# US 2025/0368992 A1 · Nucleic acid compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0368992 A1
- Document ID: US20250368992A1
- Status: Published application
- Kind: A1
- Application number: 18/876,974
- Filed: 2023-07-27
- Published: 2025-12-04
- Earliest claimed: 2022-07-27
- Assignees: E-Therapeutics PLC
- Applicants: E-Therapeutics PLC
- Inventors: Amy MCCARTHY; Graham CRAGGS; James LONGDEN; Ines DE SANTIAGO; Duncan BROWN; Ahmad Ali MORTZAAVI; Viviana MANNELLA; Muthusamy JAYARAMAN; Damian ELLE; Alison GALLAFENT; Laura ROCA-ALONSO; Alexandre DEBACKER
- Web page: https://patentgrep.com/patent/US20250368992A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/31: of the backbone
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/323: modified ring structure
- C12N 2310/332: Abasic residue
- C12N 2310/351: Conjugate
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides novel nucleic acid compounds suitable for therapeutic use. Additionally, the present invention provides methods of making these compounds, as well as methods of using such compounds for the treatment of various diseases and conditions.

## Claims

### Claim 1

A nucleic acid for inhibiting expression of a target gene, comprising a first strand that is at least partially complementary to a portion of RNA transcribed from the target gene, and a second strand that is at least partially complementary to the first strand, wherein said first and second strands form a duplex region of at least 17 nucleosides in length,
wherein the second strand comprises 2 consecutive abasic nucleosides in the 5′ terminal region of the second strand, comprise an abasic nucleoside that is a terminal nucleoside at the 5′ terminal region of the second strand and the other abasic nucleoside is a penultimate nucleoside at the 5′ terminal region of the second strand, wherein: (a) said penultimate abasic nucleoside is connected to an adjacent first basic nucleoside in an adjacent 5′ near terminal region through a reversed internucleoside linkage; (b) the reversed linkage is a 5-5′ reversed linkage; and (c) the linkage between the terminal and penultimate abasic nucleosides is 3′-5′ when reading towards the terminus comprising the terminal and penultimate abasic nucleosides, and
wherein said first strand comprises at least one thermally destabilizing modification of the duplex within the first 9 nucleoside positions of the 5′ region thereof.

### Claim 2

A nucleic acid for inhibiting expression of a target gene, comprising a first strand that is at least partially complementary to a portion of RNA transcribed from the target gene, and a second strand that is at least partially complementary to the first strand, wherein said first and second strands form a duplex region of at least 17 nucleosides in length, and wherein nucleosides of said second strand comprise a 2′ sugar and abasic modification pattern as follows (5′-3′):
wherein ia represents an inverted abasic nucleoside, and
wherein said first strand comprises at least one thermally destabilizing modification of the duplex within the first 9 nucleoside positions of the 5′ region thereof.

### Claim 3 (depends on 1, 2)

A nucleic acid according to claim 1 or 2, wherein the destabilizing modification is selected from an Unlocked Nucleic Acid (UNA) and a Glycol Nucleic Acid (GNA).

### Claim 4 (depends on 3)

A nucleic acid according to claim 3, wherein the destabilizing modification comprises at least one Unlocked Nucleic Acid (UNA).

### Claim 5 (depends on 3)

A nucleic acid according to claim 3, wherein the destabilizing modification comprises at least one Glycol Nucleic Acid (GNA), in particular at least one (S)-Glycol Nucleic Acid.

### Claim 6

A nucleic acid according to any preceding claim, wherein said at least one thermally destabilizing modification of the duplex is within nucleoside positions 2 to 9 of the 5′ region of said first strand, preferably nucleoside positions 2 to 8, more preferably nucleoside positions 3 to 8, more preferably nucleoside positions 4 to 8, and most preferably at nucleoside position 6 or 7.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A nucleic acid according to any of claims 1 to 6, wherein nucleosides of said first strand comprise a 2′ sugar modification pattern wherein said modifications are selected at least from 2′Me and 2′F sugar modifications, provided that the overall number of 2′F sugar modifications in the first strand does not consist of four, or six, 2′F modifications.

### Claim 8 (depends on 7)

A nucleic acid according to claim 7, wherein nucleosides of said first strand comprise a 2′ sugar modification pattern wherein said modifications are selected at least from 2′Me and 2′F sugar modifications, wherein the overall number of 2′F sugar modifications in the first strand consists of three, five or seven 2′F modifications.

### Claim 9 (depends on 8)

A nucleic acid according to claim 8, wherein nucleosides of said first strand comprise a 2′ sugar modification pattern wherein said modifications are selected at least from 2′Me and 2′F sugar modifications, wherein the overall number of 2′F sugar modifications in the first strand consists of three 2′F modifications.

### Claim 10 (depends on 8)

A nucleic acid according to claim 8, wherein nucleosides of said first strand comprise a 2′ sugar modification pattern wherein said modifications are selected at least from 2′Me and 2′F sugar modifications, wherein the overall number of 2′F sugar modifications in the first strand consists of five 2′F modifications.

### Claim 11 (depends on 8)

A nucleic acid according to claim 8, wherein nucleosides of said first strand comprise a 2′ sugar modification pattern wherein said modifications are selected at least from 2′Me and 2′F sugar modifications, wherein the overall number of 2′F sugar modifications in the first strand consists of seven 2′F modifications.

### Claim 12 (depends on 9)

A nucleic acid according to claim 9, wherein nucleosides of said first strand comprise a 2′ sugar modification pattern as follows (5′-3′):
wherein X1 is a thermally destabilising modification.

### Claim 13 (depends on 10)

A nucleic acid according to claim 10, wherein nucleosides of said first strand comprise a 2′ sugar modification pattern as follows (5′-3′):
wherein X1 is a thermally destabilising modification.

### Claim 14

A nucleic acid according to any preceding claim, wherein two phosphorothioate internucleoside linkages are respectively present between three consecutive positions in a 5′ near terminal region of the second strand, wherein a first phosphorothioate internucleoside linkage is present between a first basic nucleoside when reading from the 5′ terminus and an adjacent second basic nucleoside in said 5′ near terminal region of the second strand, and a second phosphorothioate internucleoside linkage is present between said second basic nucleoside and an adjacent third basic nucleoside in said 5′ near terminal region of the second strand.

### Claim 15

A nucleic acid according to any preceding claim, wherein two phosphorothioate internucleoside linkages are respectively present between three consecutive positions in both 5′ and 3′ terminal regions of the first strand, whereby a terminal nucleoside respectively at each of the 5′ and 3′ terminal regions of said first strand is each attached to a respective 5′ and 3′ adjacent penultimate nucleoside by a phosphorothioate internucleoside linkage, and each 5′ and 3′ penultimate nucleoside is attached to a respective 5′ and 3′ adjacent antepenultimate nucleoside by a phosphorothioate internucleoside linkage.

### Claim 16

A nucleic acid for inhibiting expression of a target gene, comprising a first strand that is at least partially complementary to a portion of RNA transcribed from the target gene, and a second strand that is at least partially complementary to the first strand, wherein said first and second strands form a duplex region of at least 17 nucleosides in length, and wherein nucleosides of said second strand comprise a 2′ sugar, and abasic modification pattern as follows (5′-3′):
wherein ia represents an inverted abasic nucleoside, and
wherein nucleosides of said first strand comprise a 2′ sugar modification pattern selected from one of the following (5′-3′):
Me-F-(Me)3-X1-(Me)7-F-Me-F-(Me)7, wherein X1 is a thermally destabilising modification
Me-F-(Me)3-X1-Me-(F)2-(Me)4-F-Me-F-(Me)7, wherein X1 is a thermally destabilising modification.

### Claim 17

A nucleic acid for inhibiting expression of a target gene, comprising a first strand that is at least partially complementary to a portion of RNA transcribed from the target gene, and a second strand that is at least partially complementary to the first strand, wherein said first and second strands form a duplex region of at least 17 nucleosides in length, and wherein nucleosides of said second strand comprise a 2′ sugar, and abasic modification pattern as follows (5′-3′):
wherein ia represents an inverted abasic nucleoside, and (s) represents a phosphorothioate linkage, wherein nucleosides of said first strand comprise a 2′ sugar modification pattern selected from one of the following (5′-3′):
Me(s)F(s)(Me)3-X1-(Me)7-F-Me-F-(Me)5(s)Me(s)Me, wherein X1 is a thermally destabilising modification
Me(s)F(s)(Me)3-X1-Me-(F)2-(Me)4-F-Me-F-(Me)5(s)Me(s)Me, wherein X1 is a thermally destabilising modification

### Claim 18 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A nucleic acid according to any of claims 2 to 17, wherein the 2 consecutive abasic nucleosides in the 5′ terminal region of the second strand, comprise an abasic nucleoside that is a terminal nucleoside at the 5′ terminal region of the second strand and the other abasic nucleoside is a penultimate nucleoside at the 5′ terminal region of the second strand, wherein: (a) said penultimate abasic nucleoside is connected to an adjacent first basic nucleoside in an adjacent 5′ near terminal region through a reversed internucleoside linkage; (b) the reversed linkage is a 5-5′ reversed linkage; and (c) the linkage between the terminal and penultimate abasic nucleosides is 3′-5′ when reading towards the terminus comprising the terminal and penultimate abasic nucleosides.

### Claim 19

A nucleic acid according to any preceding claim, wherein the second strand of the nucleic acid is conjugated directly or indirectly to the one or more ligand moieties at the 3′ terminal region of the second strand.

### Claim 20 (depends on 19)

A nucleic acid according to claim 19, wherein the ligand moiety comprises:
one or more N-acetyl galactosamine (GalNAc) ligands, and/or
one or more N-acetyl galactosamine (GalNAc) ligand derivatives, and/or
one or more N-acetyl galactosamine (GalNAc) ligands and/or derivatives thereof,
conjugated to the nucleic acid through a linker.

### Claim 21 (depends on 20)

A nucleic acid according to claim 20, having the structure:
wherein:
R1 at each occurrence is independently selected from the group consisting of hydrogen, methyl and ethyl;
R2 is selected from the group consisting of hydrogen, hydroxy, —OC1-3alkyl, —C(═O)OC1-3alkyl, halo and nitro;
X1 and X2 at each occurrence are independently selected from the group consisting of methylene, oxygen and sulfur;
m is an integer of from 1 to 6;
n is an integer of from 1 to 10;
q, r, s, t, v are independently integers from 0 to 4, with the proviso that:
(i) q and r cannot both be 0 at the same time; and
(ii) s, t and v cannot all be 0 at the same time;
Z is an oligonucleoside.

### Claim 22 (depends on 20)

A nucleic acid according to claim 20, having the structure:
wherein:
r and s are independently an integer selected from 1 to 16; and
Z is an oligonucleoside.

### Claim 23

A nucleic acid according to any preceding claim, wherein the nucleic acid is an siRNA oligonucleoside.

### Claim 24

A pharmaceutical composition comprising a nucleic acid according to any preceding claim, in combination with a pharmaceutically acceptable excipient or carrier.

### Claim 25

A nucleic acid or pharmaceutical composition according to any preceding claim, for use in therapy.

### Claim 26

A nucleic acid or pharmaceutical composition according to any preceding claim, for use in prevention or treatment of a disease related to a disorder of haemostasis, such as a disease related to a disorder of haemostasis, such as haemophilia.

### Claim 27

A nucleic acid or pharmaceutical composition according to any preceding claim, for use in prevention or treatment of diabetes.

### Claim 28

A nucleic acid or pharmaceutical composition according to any preceding claim, for use in prevention or treatment of cardiovascular disease.
